Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, November 2001, p. 3065-3069, Vol. 45, No. 11
Mycotic Diseases Branch, Division of Bacterial and Mycotic
Diseases, National Center for Infectious Diseases, Centers for Disease
Control and Prevention,1 and Veterans
Administration Medical Center and Emory University School of
Medicine,6 Atlanta, Georgia;
Department of Pathology, University of Iowa College of
Medicine, Iowa City, Iowa2; Veterans
Administration Medical Center and Baylor College of Medicine,
Houston, Texas3; Department of Medicine,
University of Alabama at Birmingham, Birmingham,
Alabama4; and School of Public
Health, University of California at Berkeley, Berkeley,
California5
Received 7 May 2001/Returned for modification 14 July 2001/Accepted 3 August 2001
The antifungal drug susceptibilities of two collections of
Cryptococcus neoformans isolates obtained
through active laboratory-based surveillance from 1992 to 1994 (368 isolates) and 1996 to 1998 (364 isolates) were determined. The MICs of
fluconazole, itraconazole, and flucytosine were determined by the
National Committee for Clinical Laboratory Standards broth
microdilution method; amphotericin B MICs were determined by the
E-test. Our results showed that the MIC ranges, the MICs at which 50%
of isolates are inhibited (MIC50s), and the
MIC90s of these four antifungal agents did not change from
1992 to 1998. In addition, very small numbers of isolates showed
elevated MICs suggestive of in vitro resistance. The MICs of
amphotericin B were elevated (
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.11.3065-3069.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Trends in Antifungal Drug Susceptibility of Cryptococcus
neoformans Isolates in the United States: 1992 to 1994 and
1996 to 1998
for the Cryptococcal
Disease Active Surveillance Group
2 µg/ml) for 2 isolates, and the MICs
of flucytosine were elevated (
32 µg/ml) for 14 isolates. Among the
azoles, the fluconazole MIC was elevated (
64 µg/ml) for 8 isolates
and the itraconazole MIC (
1 µg/ml) was elevated for 45 isolates. Analysis of 172 serial isolates from 71 patients showed little change in the fluconazole MIC over time. For
isolates from 58 patients (82% of serial cases) there was either no
change or a twofold change in the fluconazole MIC. In contrast, for
isolates from seven patients (12% of serial cases) the increase in the MIC was at least fourfold. For isolates from another patient there was
a 32-fold decrease in the fluconazole MIC over a 1-month
period. We conclude that in vitro resistance to antifungal agents
remains uncommon in C. neoformans and has not
significantly changed with time during the past decade.
*
Corresponding author. Mailing address: Mycotic Diseases
Branch, Centers for Disease Control and Prevention, 1600 Clifton Rd., N.E., Mailstop G-11, Atlanta, GA 30333. Phone: (404) 639-0281. Fax:
(404) 639-3546. E-mail: Mbrandt{at}cdc.gov.
Study group members are listed in the appendix.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |